GlobeNewswire

Compuware Acquires XaTester and Partners with Parasoft to Deliver Essential Automated Unit Testing to Mainframe DevOps Teams

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=63b6178d-f04f-4003-9f2a-fca7ad9a8f2e&maxHeight=150&maxWidth=150

Topaz Further Established as the Leading Solution for Continuously Improving Velocity, Quality and Efficiency of Enterprise Systems

  • Large enterprises must rigorously safeguard the quality of their mission-critical mainframe systems as digital demands drive them to develop and deploy mainframe code more quickly and frequently. 
  • With the acquisition of XaTester, new enhancements, and partnership with Parasoft, Compuware Topaz for Total Test is the clear leader in the automated unit testing essential for Agile and DevOps on the mainframe.
  • With Topaz, developers at all skill levels can quickly and efficiently produce the highest-quality code for the mainframe-enabling enterprises to achieve the digital agility essential for success in fast-moving markets.             

DETROIT, July 18, 2018 (GLOBE NEWSWIRE) -- Compuware today announced a product acquisition, enhancements to Topaz for Total Test, and a partnership that together dramatically improve the ability of large enterprises to embrace Agile and DevOps on their mainframes through the broader use of simplified, automated unit testing-which is essential for fast, safe and efficient development and deployment of new digital deliverables.

To deliver on its vision of Topaz for Total Test as the de facto standard for automating mainframe unit testing across all major mainframe environments and programming languages, Compuware has:

  • Acquired XaTester from Xact Consulting A/S, enabling developers to quickly create unit tests for both batch and CICS-based programs written in COBOL, PL/I and Assembler. CICS is especially important as the transaction processing technology of choice for many of the world's largest enterprises-especially financial institutions and insurance companies-due to its extremely high integrity, performance and scalability.
     
  • Enhanced Topaz for Total Test to provide automated unit testing for IMS batch and transactional applications. Testing for IMS is especially important given that contemporary developers often have little or no hands-on experience with IMS code. These enhancements complement Topaz for Total Test's existing support for batch applications written in COBOL-as well as its integration with leading cross-platform DevOps tools such as Jenkins, SonarSource SonarQube and Compuware ISPW.
     
  • Partnered with Parasoft, a leading innovator in end-to-end test automation for software development. The first deliverable for the partnership is integration between Parasoft SOAtest and Topaz for Total Test. This integration enables developers working on mainframe applications to quickly and easily test API calls between mainframe and non-mainframe systems.

Topaz for Total Test fundamentally transforms mainframe development by giving developers the same type of unit testing capabilities on the mainframe they've become accustomed to on other platforms. Unit testing is a fundamental requirement for modern software development. It enables developers to find potential problems in their code as early as possible, to more quickly and frequently deliver incremental changes in software functionality, and to more granularly document code for the benefit of other developers.

The result for large enterprises is a unified DevOps toolchain that accelerates development across all platforms-including the mainframe-so they can more effectively compete in today's rapidly-changing markets.

"XaTester and Topaz for Total Test are two great and complementary products for automating mainframe unit testing, which is essential to DevOps," said Steen Brahe, Senior Product Manager, Compuware (formerly from Xact Consulting). "The unified tool will leverage the best from both products and fundamentally change how customers create, execute and automate unit and integration tests for mainframe applications."

"The XaTester unit testing software has proven its value. I am pleased that Compuware will work to blend its capabilities with Topaz for Total Test as it will benefit all mainframe customers," said Elvin Høyer, CEO at Xact Consulting.   

"The new rules of the digital economy are putting pressure on our customers to achieve the utmost speed with the utmost quality," said Luke Tuddenham, Vice President at CPT, a global IT consulting services firm with a significant testing practice. "With today's announcements, Compuware has again demonstrated its leadership in innovative automated testing technologies for the mainframe that will help us help our clients to achieve this critical goal."

Compuware Topaz, a comprehensive suite of solutions, provides DevOps professionals at all skill levels with a visually intuitive environment where they can effectively understand and work on any mainframe application-regardless of age, complexity or lack of documentation. This simplified, streamlined approach is especially important as responsibility for applications running on the platform shifts from IT professionals with decades of mainframe-specific experience to a new generation of DevOps artisans who are more familiar with mainstream technologies such as Java and C++.

"REST and SOAP APIs provide the backbone of today's business-critical applications, especially when these services are used to access the power of the mainframe." said Parasoft VP of Products, Mark Lambert. "Test automation at the API layer is essential to delivering high quality at the speed of Agile and the Parasoft SOAtest plugin for Topaz brings API test automation directly to the mainframe developer, helping ensure the delivery of reliable, scalable and secure services."

Today's announcement comes during the 15th consecutive quarter that Compuware has delivered significant innovations that help large enterprises mainstream the mainframe, so they can better leverage the platform's unmatched performance, scalability, reliability, efficiency and security.

"Large enterprises increasingly recognize that digital innovation in the cloud must be paired with digital innovation on the mainframe," said Chris O'Malley, CEO of Compuware. "Compuware's passion and support for this mainframe-based digital innovation is unmatched-as we have once again demonstrated with this latest round of aggressive deliverables that enable Agile and DevOps best practices on the platform."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum